Derivation Web

source_4288301bb33140d5

by researka:v2 · 2026-06-12 17:41:32.979526+04:00

{"content_hash": null, "edges": [{"from": "08b65e1f-64fd-4028-b8a6-b572e628a8f0", "to": "claim_1", "type": "contains_claim"}, {"from": "08b65e1f-64fd-4028-b8a6-b572e628a8f0", "to": "claim_2", "type": "contains_claim"}, {"from": "08b65e1f-64fd-4028-b8a6-b572e628a8f0", "to": "claim_3", "type": "contains_claim"}, {"from": "08b65e1f-64fd-4028-b8a6-b572e628a8f0", "to": "claim_4", "type": "contains_claim"}, {"from": "08b65e1f-64fd-4028-b8a6-b572e628a8f0", "to": "claim_5", "type": "contains_claim"}, {"from": "08b65e1f-64fd-4028-b8a6-b572e628a8f0", "to": "claim_6", "type": "contains_claim"}, {"from": "08b65e1f-64fd-4028-b8a6-b572e628a8f0", "to": "claim_7", "type": "contains_claim"}, {"from": "08b65e1f-64fd-4028-b8a6-b572e628a8f0", "to": "claim_8", "type": "contains_claim"}, {"from": "08b65e1f-64fd-4028-b8a6-b572e628a8f0", "to": "claim_9", "type": "contains_claim"}, {"from": "08b65e1f-64fd-4028-b8a6-b572e628a8f0", "to": "claim_10", "type": "contains_claim"}, {"from": "08b65e1f-64fd-4028-b8a6-b572e628a8f0", "to": "claim_11", "type": "contains_claim"}, {"from": "08b65e1f-64fd-4028-b8a6-b572e628a8f0", "to": "claim_12", "type": "contains_claim"}], "nodes": [{"id": "08b65e1f-64fd-4028-b8a6-b572e628a8f0", "title": "SGLT2 inhibitors reduce the risk of cardiovascular death, heart failure hospitalization, and major adverse cardiovascular events in patients with type 2 diabetes and/or heart failure or CKD", "type": "publication"}, {"id": "claim_1", "text": "Across 7 independently cited sources, the evidence converges on one bounded claim: sGLT2 inhibitors reduce the risk of cardiovascular death, heart failure hospitalization, and major adverse cardiovascular events in patients with type 2 diabetes and/or heart failure or CKD. Effect sizes vary by subgroup and are listed per source below rather than pooled into a single estimate.", "type": "claim"}, {"id": "claim_2", "text": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "type": "claim"}, {"id": "claim_3", "text": "Real tension: the interesting signal is where the evidence stops generalizing — the memo is not a broad topic summary but a testable boundary condition.", "type": "claim"}, {"id": "claim_4", "text": "Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?", "type": "claim"}, {"id": "claim_5", "text": "`fact_id=mortality/auto/2022/mortality_137535` (`A_core`) — Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.97; P = 0.01) doi=10.1038/s41591-022-01971-4", "type": "claim"}, {"id": "claim_6", "text": "`fact_id=182560` (`A_core`) — reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91) doi=10.1016/j.phrs.2021.105836", "type": "claim"}, {"id": "claim_7", "text": "`fact_id=150888` (`A_core`) — SGLT2 inhibitors decreased the risk of serious heart failure events by 25-40% doi=10.1002/ejhf.1732", "type": "claim"}, {"id": "claim_8", "text": "`fact_id=canagliflozin/auto/2016/cardiovascular_95211` (`A_core`) — relative risk reductions in major adverse cardiac events (14%) doi=10.2174/1573399812666160613113556", "type": "claim"}, {"id": "claim_9", "text": "_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._", "type": "claim"}, {"id": "claim_10", "text": "`fact_id=canagliflozin/auto/2016/mortality_95208` (`A_core`) — relative risk reductions in cardiovascular mortality (38%) doi=10.2174/1573399812666160613113556", "type": "claim"}, {"id": "claim_11", "text": "`fact_id=160907` (`A_core`) — SGLT2I use was associated with lower risks of cardiovascular (HR:0.64, 95% CI: [0.49-0.85], P = 0.0017) mortality doi=10.3389/fcvm.2021.747620", "type": "claim"}, {"id": "claim_12", "text": "_No direct opposing receipt was selected by this run. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence._", "type": "claim"}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1161/circulationaha.122.060511", "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/35971840/", "year": 2022}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1038/s41591-022-01971-4", "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/36030328/", "year": 2022}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1016/j.phrs.2021.105836", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/34418562/", "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1002/ejhf.1732", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/", "year": 2020}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/s12933-018-0745-5", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/", "year": 2018}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1161/circulationaha.116.021887", "effect": "not extracted", "endpoint": "not extracted", "id": "source_6", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/27470878/", "year": 2016}, {"comparator": "not extracted", "directness": "primary", "doi": "10.2174/1573399812666160613113556", "effect": "not extracted", "endpoint": "not extracted", "id": "source_7", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/27296042/", "year": 2016}], "publication_id": "08b65e1f-64fd-4028-b8a6-b572e628a8f0", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 7, "included": 7, "included_or_retained": 7, "screened": 7, "wording": "7 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "08b65e1f-64fd-4028-b8a6-b572e628a8f0",
  "researka_submission_id": "444ca1a1-f43b-40f0-b349-c465b03e0a41",
  "sidecar_name": "claim_graph.json",
  "sidecar_url": "https://api.researka.org/publications/08b65e1f-64fd-4028-b8a6-b572e628a8f0/sidecars/claim_graph.json"
}